Concord Drugs sets Sep 23 record date for 31st AGM
- Concord Drugs sets September 23, 2026, as the record date for its 31st AGM
- The annual general meeting is scheduled for September 30, 2026, via VC/OAVM
- Book closure period runs from September 24 to September 30, 2026
- Eligible shareholders can cast electronic votes during the meeting

*this image is generated using AI for illustrative purposes only.
Concord Drugs has fixed Wednesday, September 23, 2026, as the cut-off date for determining shareholders eligible to vote at its 31st Annual General Meeting. The meeting is scheduled for September 30, 2026.
The company notified BSE Limited on September 7, 2026, pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice included the submission of the Annual Report for FY26.
Meeting Details
The AGM will be held on Wednesday, September 30, 2026, starting at 9:30 am. It will be conducted through Video Conferencing or Other Audio Visual Means (VC/OAVM), in compliance with circulars from the Ministry of Corporate Affairs and SEBI.
Shareholder Eligibility and Book Closure
The Register of Members, Share Transfer Books, and other company books will remain closed from September 24, 2026, to September 30, 2026, inclusive. This closure is mandated under Section 91 of the Companies Act, 2013, and Regulation 42 of the SEBI (LODR) Regulations, 2015.
Shareholders on record as of September 23, 2026, will be eligible to cast electronic votes. The Annual Report is available on the company’s website.
Historical Stock Returns for Concord Drugs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.39% | -1.76% | +11.89% | +10.68% | +24.53% | 0.0% |
What key financial metrics or strategic initiatives from FY26 are likely to be highlighted in the Annual Report submitted to BSE?
How might the resolution of any special business items at the AGM impact Concord Drugs' future dividend policy or capital allocation strategy?
Are there any anticipated changes to the board composition or management structure that shareholders should prepare for during the vote?


































